Jul. 21 at 2:06 AM
$ARMP People keep overlooking one of ARMP’s biggest advantages: leadership.
CEO Dr. Deborah Birx is one of the most politically connected figures in public health. Those relationships and decades of experience have helped position Armata to secure DoD funding and engage closely with the FDA on programs addressing urgent antimicrobial resistance.
The DoD doesn’t hand out contracts without seeing strategic value, and FDA attention reflects the need for new therapies in a space with few effective options.
Execution still matters, but strong leadership, government backing, and a massive unmet medical need make
$ARMP one of the more interesting biotech stories to watch.
